Resources for students such as educational tools covering a variety of managed care topics and information on professional opportunities (internships, APPEs, fellowships and residencies) related to managed care pharmacy.
Pharmacy benefit manager (PBM) reform is evolving rapidly at the state level, creating a complex and often fragmented policy landscape that stakeholders must actively monitor. Understanding which reforms are advancing in each state is critical, as these policies can significantly alter drug pricing dynamics, rebate structures, formulary design, and patient access.
In partnership with Health Care Now Radio and Answers Media Network, segment with Harry Travis representing AMCP with other health care experts in a virtual event focused on real-world deployments, practical lessons, and candid conversations about what delivers results.
AMCP members gathered in Washington, DC, on May 18–20 for Legislative Days 2026, to advocate for managed care's legislative priorities addressing patient access, affordability, and care delivery.
A federal district court in Georgia issued a sweeping ruling that could potentially undermine the legal foundation of the Medicare Advantage (MA) Star Ratings program and invite additional challenges to policies established through sub-regulatory guidance. The court found that the Centers for Medicare and Medicaid Services (CMS) improperly relied on measures based on data not collected through the statutorily required measurement systems and failed to meet notice-and-comment requirements for certain measures.
On June 3, 2026, the Centers for Medicare and Medicaid Services (CMS) released educational materials for the Medicare GLP-1 Bridge program.
The Medicare GLP-1 Bridge program will start on July 1, 2026. Through this short-term demonstration, CMS will be expanding access to certain GLP-1 medications to eligible Medicare Part D beneficiaries who do not currently have access to these medications through the Part D benefit.
The bipartisan Main Street Pharmacy Access Act (H.R. 3164/S. 2426), which would allow Medicare to reimburse pharmacists for testing and treating certain respiratory illnesses in states that already authorize those services, cleared the House Committee on Ways and Means on May 21, 2026.
On June 1, 2026, the Centers for Medicare and Medicaid Services issued an interim final rule (IFR) with comment period to implement provisions in Public Law 119-21 (also known as “H.R. 1” or the "One Big Beautiful Bill Act").
